In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), the ARB valsartan was shown to be as effective as captopril used at the same dose as in SAVE, and the ability of ACE inhibitors and ARB to attenuate adverse LV remodelling is believed to be related to the clinical benefits of these treatments.14, 28, 29. This evidence concerns the gene ACE and myocardial infarction.